Clinical trials evaluating semaglutide safety, including the SUSTAIN and STEP trial programs which enrolled thousands of participants, did not identify UTIs as a significant adverse event associated with the medication
The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis
[DOI] [PMC free article] [PubMed] [Google Scholar] 187
Further investigations are warranted to validate these findings in East Asian populations, including Japanese cohorts
Specific symptoms warranting urgent consultation include: Severe or persistent vomiting lasting more than 24 hours, which may lead to dehydration and electrolyte imbalance Signs of dehydration , including reduced urination, dark urine, dizziness, or confusion Severe, persistent abdominal pain , particularly if radiating to the back and accompanied by fever or vomiting, which could indicate pancreatitis (a rare but serious adverse effect of GLP-1 receptor agonists) Symptoms of hypoglycaemia that are frequent, severe, or not responding to usual management strategies Worsening depression, anxiety, or suicidal thoughts , which require immediate mental health assessment Unexpected or concerning symptoms with weight loss (e.g., profound fatigue, dehydration) Routine follow-up appointments should be scheduled according to NICE guidance for diabetes management (NG28), typically every 36 months once treatment is stabilised
